Thrombosis Primer: What you need to know about NOACs for AF and VTE

Details & Video

What you need to know about NOACs for AF and VTE

Video Time: 37 minutes
Program Interactivity: 5-15 min
Accreditation-CME Credits: This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+ credits. This program is eligible for both Section 1 credits as well as AMA PRA Category 1.
Target Audience: Cardiologists, Internists, General Practitioners
Program available until: February 16, 2018
Program Preview
Click image above to play the program preview.
To watch the full program, please login or register

Overview & Objectives

Thrombosis Primer

Target Audience: Cardiologists, Internists, General Practitioners.

Program Outline: Stroke prevention remains a number one priority in managing patients with atrial fibrillation. Recent guideline updates have tried to simplify the approach to risk assessment for stroke. While warfarin remains a standard of care, novel oral anticoagulants (NOAC) are increasingly being used for efficacy, safety, and convenience. With multiple NOAC available, and several dosing strategies for each NOAC, clinicians are faced with complex decision-making in selecting the right drug and dose for the right patient. By providing clinically relevant messages and case examples, this online program will help the busy clinician sort through the various options for stroke prevention in AF. Importantly, emphasis will be placed on maximizing safety and selection of the most appropriate dose of each drug.

Learning Objectives:
  1. Discuss the risks associated with VTE and treatment strategies with newer OAC agents.
  2. Understand the safety and efficacy of NOAC's for stroke prevention by analyzing real world registry data compared with clinical trial findings.
  3. Apply latest AF stroke prevention guidelines to high risk subgroups of AF patients.



Accreditation

This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+ credits.


This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program. This program is approved by the Canadian Cardiovascular Society for a maximum of 1 credits.

Credits for Family Physicians:
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+ credits.

This program was supported in part by an educational grant from Bristol-Myers Squibb and Pfizer Canada.

Claiming your credits: Please submit your credits for this activity online at www.cfpc.ca/login. Please retain proof of your participant for six (6) years in case you are selected to participate in credit validation or auditing.

Planning Committee

Planning Committee

Milan Gupta
Milan Gupta
FRCPC, FACC
Brampton, ON


Paul Dorian
Paul Dorian
MD, Msc, FRCPC
Toronto, ON


André Roussin
André Roussin
MD, FRCPC
Montreal, QC


Carl Fournier
Carl Fournier
MD, CCFP
Montréal, QC


Daniel Ngui
Daniel Ngui
BSc (P.T), MD, CFPC, FCFP
Vancouver, ON


Sol Stern
Sol Stern
Bsc, MSc MD MCFP
Oakville, ON


Faculty

Faculty

Milan Gupta
Chair
Milan Gupta
FRCPC, FACC

Associate Clinical Professor, Dep’t of Medicine
McMaster University

Assistant Professor, Dep’t of Medicine
University of Toronto

Medical Director
Canadian Cardiovascular Research Network

View disclosures

Brampton, ON
Paul Dorian
Paul Dorian
MD, Msc, FRCPC

Department Director, Division of Cardiology, and Staff Cardiac Electrophysiologist, St. Michael’s Hospital
Professor of Medicine, Division of Cardiology and Division of Clinical Pharmacology, University of Toronto, Toronto, ON, Canada
View disclosures

Toronto, ON
André Roussin
André Roussin
MD, FRCPC

Internal medicine, Associate Professor of Medicine, Department of Medicine, University of Montreal
Director, Vascular laboratory, Notre-Dame Hospital/CHUM, Vice-President, THROMBOSIS CANADA
Past president and secretary-treasurer, Quebec Society of Vascular Sciences (QSVS), Montreal, QC, Canada
View disclosures

Montreal, QC

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Chapter 1: Introduction2:10
Chapter 2: NOACs in venous thromboembolism15:37
Chapter 3: NOACs for stroke prevention in AF; 2016 Update6:04
Chapter 4: Bleeding risk and reversal agents11:22


Sponsorship

CCRN sm

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:

Bristol-Myers Squibb and Pfizer Canada

Links & Resources

Links & Resources:

  • Agnelli et al., N Engl J Med. 2013;369:799-808
  • Schulman et al., Circulation. 2014;129:764-72
  • Dabigatran (Pradaxa) Product Monograph. Boehringer Ingelheim Canada Ltd.
  • EINSTEIN Investigators et al., N Engl J Med. 2010;363:2499-510
  • EINSTEIN–PE Investigators et al,. N Engl J Med. 2012;366:1287-97
  • Agnelli et al., NEJM. 2013;368:699-708
  • Schulman et al. NEJM. 2013;368:709-18
  • 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol 2014:30(10). Pages 1114–1130
  • Oldgren et al., Circulation 2014 Jan 24 (epub ahead of print)
  • Ruff CT et al., Lancet 2013 Dec 3; doi: 10.1016/S0140-6736(13)62343-0
  • John Camm et al., on behalf of the XANTUS Investigators DOI: http://dx.doi.org/10.1093/eurheartj/ehv466 ehv466 First published online: 1 September 2015
  • Mary Ross Southworth et al., N Engl J Med 2013; 368:1272-1274 April 4, 2013 DOI: 10.1056/NEJMp1302834
  • Lip GYH et al., ESC 2015, London, UK. Poster P6217, ESC 2015. Accessible on congress365.escardio.org
  • Capranzano P, et al., Expert Rev Cardiovasc Ther 2013;11:959-73